Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response

被引:114
|
作者
Becker, Matthijs L. [1 ,4 ]
Visser, Loes E. [1 ,4 ]
van Schaik, Ron H. N. [2 ,5 ]
Hofman, Albert [1 ]
Uitterlinden, Andre G. [1 ,3 ]
Stricker, Bruno H. Ch. [1 ,3 ,6 ]
机构
[1] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Clin Chem, NL-3000 CA Rotterdam, Netherlands
[3] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[4] Erasmus MC, Dept Hosp Pharm, NL-3000 CA Rotterdam, Netherlands
[5] STAR Med Diagnost Ctr, Rotterdam, Netherlands
[6] Inspectorate Hlth Care, Drug Safety Unit, The Hague, Netherlands
来源
PHARMACOGENETICS AND GENOMICS | 2010年 / 20卷 / 01期
关键词
diabetes mellitus type II; metformin; organic cation transporter 1; organic cation transporter proteins; pharmacogenetics; ORGANIC CATION TRANSPORTER-1; GENETIC-VARIATION; MULTIDRUG; PROTEIN;
D O I
10.1097/FPC.0b013e328333bb11
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective Metformin is transported into the hepatocyte by organic cation transporter 1 (OCT1) and out of the hepatocyte by multidrug and toxin extrusion 1 (MATE1). Recently, we discovered that polymorphisms rs622342 A>C in the SLC22A1 gene, coding for OCT1, and rs2289669 G>A in the SLC47A1 gene, coding for MATE1, are associated with the degree of glucose lowering by metformin. In this study, we assessed whether there exists an interaction between these two polymorphisms. Methods We identified all incident metformin users in the Rotterdam Study, a population-based cohort study. Multiplicative interaction between the polymorphisms and change in HbA1c levels was analyzed in 98 incident metformin users. Results In incident metformin users with the OCT1 rs622342 AA genotype, genetic variation at the MATE1 rs2289669 polymorphism was not associated with change in HbA1c levels [-0.10; 95% confidence interval (CI): -0.35 to 0.14; P=0.39]. In users with the OCT1 rs622342 AC genotype, there was a tendency between rs2289669 polymorphisms and change in HbA1c (-0.31; 95% CI: -0.65 to 0.03; P = 0.070) and in users with the OCT1 rs622342 CC genotype there was a significant association with change in HbA1c levels (-0.68; 95% CI: -1.06 to -0.30; P = 0.005). The multiplicative interaction between these two genotypes was statistically significant (-0.52; 95% CI: - 0.94 to -0.11; P = 0.015). Conclusion The effect of the MATE1 rs2289669 polymorphism on the glucose lowering effect of metformin is larger in incident users with the OCT1 rs622342 CC genotype than in incident users with the AA genotype. The effect in incident users with the OCT1 rs622342 AC genotype is in between. Pharmacogenetics and Genomics 20:38-44 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:38 / 44
页数:7
相关论文
共 50 条
  • [1] INTERACTION BETWEEN GENETIC VARIANTS IN THE TRANSPORTERS, OCT1 AND MATE1, AND GLYCEMIC RESPONSE TO METFORMIN
    Yee, S.
    Jenkins, G.
    Joshki, P.
    Savic, R. M.
    Mefford, J. A.
    Hemmes, M. A.
    Witte, J. S.
    Wilke, R. A.
    McCarty, C. A.
    Davis, R. L.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S2 - S2
  • [2] INTERACTION BETWEEN GENETIC VARIANTS IN THE TRANSPORTERS, OCT1 AND MATE1, AND GLYCEMIC RESPONSE TO METFORMIN.
    Yee, S.
    Jenkins, G.
    Joshki, P.
    Savic, R. M.
    Mefford, J. A.
    Hemmes, M. A.
    Witte, J. S.
    Wilke, R. A.
    McCarty, C. A.
    Davis, R. L.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S37 - S37
  • [3] The Effect of Genetic Variation in OCT1, OCT2 and MATE1 on Metformin Treatment Response
    Van Leeuwen, Nienke
    Nijpels, Giel
    Dekker, Jacqueline M.
    Welschen, Laura
    'T Hart, Leen M.
    DIABETES, 2011, 60 : A387 - A387
  • [4] Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1
    Li, Liping
    Lei, Hongmei
    Wang, Wei
    Du, Weijuan
    Yuan, Jingqun
    Tu, Meijuan
    Zhou, Hui
    Zeng, Su
    Jiang, Huidi
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (09) : 411 - 419
  • [5] A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin
    Christensen, Mette M. H.
    Pedersen, Rasmus S.
    Stage, Tore B.
    Brasch-Andersen, Charlotte
    Nielsen, Flemming
    Damkier, Per
    Beck-Nielsen, Henning
    Brosen, Kim
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (10): : 526 - 534
  • [6] Genetic polymorphisms in human organic cation transporter 1 (OCT1) are determinants of metformin disposition and response.
    Shu, Y.
    Brown, C.
    Owen, R. P.
    Zhang, S.
    Castro, R. A.
    Lin, E. T.
    Lo, J.
    Burchard, E. G.
    Brett, C. M.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S7 - S8
  • [7] TYROSINE PHOSPHORYLATION MEDIATED REGULATION OF OCT1 AND MATE1 FUNCTION.
    Hu, S.
    Pabla, N.
    Gibson, A. A.
    Baker, S. D.
    Sparreboom, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S31 - S31
  • [8] Genetic polymorphisms in human organic cation transporter 1 (OCT1) are determinants of metformin disposition and response.
    Shu, Y.
    Brown, C.
    Owen, R. P.
    Zhang, S.
    Castro, R. A.
    Lin, E. T.
    Lo, J.
    Burchard, E. G.
    Brett, C. M.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S2 - S2
  • [9] The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study
    Guchelaar, Niels A. D.
    Buck, Stefan A. J.
    van Doorn, Leni
    Hussaarts, Koen G. A. M.
    Sandberg, Yorick
    van der Padt-pruijsten, Annemieke
    van Alphen, Robbert J.
    Poppe-Manenschijn, Laura
    Vleut, Isolde
    de Bruijn, Peter
    van Leeuwen, Roelof W. F.
    Mostert, Bianca
    Eskens, Ferry A. L. M.
    Oomen-de Hoop, Esther
    Koolen, Stijn L. W.
    Mathijssen, Ron H. J.
    CLINICAL PHARMACOKINETICS, 2024, 63 (07) : 1037 - 1044
  • [10] EFFECTS OF OCT2 AND MATE1 POLYMORPHISMS AND INHIBITION BY TRIMETHOPRIM ON METFORMIN PHARMACOKINETICS.
    Czock, D.
    Grun, B.
    Kiessling, M.
    Burhenne, J.
    Riedel, K.
    Weiss, J.
    Rauch, G.
    Haefeli, W. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S63 - S64